All In Biotech

Drug Trial Radar · NCT05329298

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-361175 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 21, 2021

Primary completion

Jun 30, 2023

Study completion Dec 31, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of BPI-361175 tablets in patients with advanced solid tumors including advanced Non-small cell Lung cancer (NSCLC).This is a three-stage study, consisting of Phase Ia dose escalation, Phase Ib dose expansion and pivotal Phase II Study. The pivotal Phase II study will be designed based on data generated from the Phase I studies.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • BPI-361175Drug

    Subjects will receive BPI-361175 until disease progression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: The adverse events (AEs)Time frame: Through the Phase I, approximately 24 months
  2. Phase I: Determine the recommended Phase II dose (RP2D)Time frame: Through the Phase I, approximately 24 months
  3. Phase II: the objective response rate (ORR)Time frame: Through the Phase II, approximately 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Hunan cancer hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • the First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.